HomeBEAM • BMV
add
Beam Therapeutics Inc
Nakaraang pagsara
$536.17
Sakop ng taon
$356.51 - $590.00
Market cap
2.15B USD
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Barron's
53 minuto ang nakalipas
DeepSeek Deep Sixes the Stock Market. How Far the S&P 500 Could Fall.
16.86%
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 14.27M | -17.01% |
Gastos sa pagpapatakbo | 26.52M | 4.35% |
Net na kita | -96.67M | -0.60% |
Net profit margin | -677.47 | -21.22% |
Kita sa bawat share | -1.17 | 4.10% |
EBITDA | -101.03M | 1.99% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 925.76M | -8.83% |
Kabuuang asset | 1.17B | -9.23% |
Kabuuang sagutin | 380.05M | -25.71% |
Kabuuang equity | 791.32M | — |
Natitirang share | 79.59M | — |
Presyo para makapag-book | 53.78 | — |
Return on assets | -21.89% | — |
Return on capital | -26.99% | — |
Cash Flow
Net change in cash
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -96.67M | -0.60% |
Cash mula sa mga operasyon | -88.12M | 1.85% |
Cash mula sa pag-invest | 24.70M | 341.43% |
Cash mula sa financing | 1.26M | -96.57% |
Net change in cash | -62.16M | 1.70% |
Malayang cash flow | -42.99M | -17.18% |
Tungkol
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods. Wikipedia
CEO
Itinatag
2017
Website
Mga Empleyado
472
